{"id":44888,"date":"2023-02-17T08:00:00","date_gmt":"2023-02-17T07:00:00","guid":{"rendered":"https:\/\/www.stille.se\/us\/mfn_news\/stille-ab-year-end-report-2022\/"},"modified":"2024-02-23T11:53:47","modified_gmt":"2024-02-23T10:53:47","slug":"stille-ab-year-end-report-2022","status":"publish","type":"mfn_news","link":"https:\/\/www.stille.se\/us\/news\/stille-ab-year-end-report-2022\/","title":{"rendered":"Stille AB: Year-End Report 2022"},"content":{"rendered":"
Stille AB (publ) publishes the year-end report for 2022. \u201dSolid growth and strong profit deveopment.\u201d, summarizes Niklas Carl\u00e9n, Stille\u2019s interim CEO.<\/strong><\/div>\n

Revenues increased in the fourth quarter by four percent to 61.8 (59.6) and EBIT increased by 60 percent to 8.8 MSEK (5.5). Profitability was positively affected by currency effects. For the full year 2022, sales grew by 76 percent, out of which 16 percent in organic growth. Operating profit increased to 32.4 MSEK (20.1).<\/span><\/p>\n

In the fourth quarter, business unit Surgical Table sales declined by four percent following significant component shortages. Meanwhile, Surgical Instruments increased sales by ten percent after a strong performance in Europe.<\/span><\/p>\n

\u201dWhen we summarize the year 2022, I can conclude that we have had strong organic growth within both our business units. Nine percent for Surgical Instruments and 18 percent for Surgical Tables.\u201d<\/em>, says Niklas Carl\u00e9n.\u00a0<\/span><\/p>\n

The board of directors proposes to the annual general meeting dividend of 1.80 SEK per share (1,00) for the business year 2022.<\/span><\/p>\n

\u201dWe are continuing our growth journey and I look forward to continuing this in 2023 together with Torbj\u00f6rn Sk\u00f6ld, who will be Stille\u2019s new CEO starting in March, 2023.<\/em>\u201d, concludes Stille\u2019s interim CEO.<\/span><\/p>\n\n\n\n\n\n\n\n\n\n
MSEK<\/span><\/strong><\/span><\/span><\/span><\/span><\/td>\nOCT-DEC
\n\t\t\t2022<\/span><\/strong><\/span><\/span><\/span><\/span><\/span><\/td>\n		OCT-DEC
\n\t\t\t2021<\/span><\/strong><\/span><\/span><\/span><\/span><\/span><\/td>\n		JAN-DEC
\n\t\t\t2022<\/span><\/strong><\/span><\/span><\/span><\/span><\/td>\n		JAN-DEC
\n\t\t\t2021<\/span><\/strong><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
Revenue<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n61.8<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n59.6<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n246.3<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n187.1<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
Gross Profit Margin, %<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n45.8<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n45.4<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n45.3<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n44.6<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
Operating Profit<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n8.8<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n5.5<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n32.4<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n20.1<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
Operating Profit, %<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n14.2<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n9.2<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n13.2<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n10.7<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
EBITDA<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n11.6<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n7.6<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n42.1<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n26.8<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
Net Income<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n7.7<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n5.9<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n27.3<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n16.1<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Torsh\u00e4lla, February 17th, 2023.<\/span><\/p>\n

<\/p>\n

This information is such information that Stille AB is obliged to disclose according to the EU\u2019s market abuse regulation. The information was, through the agency of the contact person, rendered for publication on February 17th, 2023, kl. 08.00 (CET).<\/em><\/p>\n

\n

For more information, please contact:<\/span><\/span><\/p>\n

Niklas Carl\u00e9n<\/span><\/span><\/strong>
\nInterim CEO and President
\n+46 (0)73 087 49 70 | niklas.carlen@stille.se<\/span><\/span><\/p>\n<\/div>\n

\n

Stille AB (publ) publ) develops, manufactures and markets medical devices for surgeons across the world. Stille was founded in 1841 and is one of the world\u2019s oldest medical device companies. Stille\u2019s main business areas are surgical instruments and c-arm tables. Stille\u2019s surgical instruments are mostly used during different kinds of open surgery. During minimal invasive procedures. the c-arm tables imagiQ2 and Medstone are key products. The company has a strong brand and products of a renowned high-quality. The share is listed on First North Growth Market under the acronym \u201cSTIL\u201d with Eminova AB as Certified Adviser, Eminova Fondkommission AB, + 46 8 684 211 10, adviser@eminova.se. For more information, visit www.stille.se.<\/span><\/span><\/p>\n<\/div>\n